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WOMEN'S HEALTH 
PMS and Eosinophilia-myalgia syndrome 
Mary E. Guinan, MD, PhD 
In November 
1989, the Centers 
for Disease Con-
trol reported a 
cluster of cases of 
the newly emerg-
ing Eosinophilia-
m y a I g i a s y n-
drome. 1 •2 First reported from New 
Mexico and associated with the in-
gestion of the amino acid L-tryp-
tophan, the number of reported cases 
has increased to more than 1 ,000 as of 
January 1990; they come from every 
state but Alaska and 84% of cases are 
in women! 
The majority of sufferers have re-
ported arthralgias, cough, shortness 
of breath, fever, and edema ofthe ex-
tremities. Periorbital edema, scleri-
dermiform skin changes, alopecia, and 
neuropathy or neuritis occurred in 
approximately 20% of cases. Eosino-
phil counts ranged from 1,000 to 
65,000 cellsjmm3• Pleural effusions 
and pulmonary infiltrates were found 
in 10% of patients who had chest 
X-rays. Thirty-six percent of patients 
were hospitalized and seven deaths 
have been reported, only one of which 
has been confirmed as directly attrib-
utable to the syndrome. 
Virtually all patients had ingested 
L-tryptophan before onset of symp-
toms. L-tryptophan is marketed as a 
food supplement in grocery stores and 
health food establishments as well as 
drug stores. Despite lack of sound ev-
idence, it has been advocated as a 
treatment for premenstrual syndrome 
(PMS) and insomnia. The PMS con-
nection may explain the preponder-
ance of cases in women. L-tryptophan 
has been touted as a natural antide-
pressant and hypnotic. So-called nat-
ural treatments are very appealing to 
a large proportion of the population, 
especially in this health conscious era. 
For women who suffer from PMS, I 
imagine that it is particularly appeal-
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ing because of the lack of a univer-
sally accepted treatment for PMS. 
Many different PMS treatments 
have been advocated, including high 
doses of specific or multiple vitamins, 
but nothing has been shown effective 
when studied in appropriate con-
trolled trials. Herein lies the dilemma: 
What can we do for patients suffering 
from PMS? Our obligation as physi-
cians is first, to do no harm, but also 
to minister to our patients' needs. 
When we recommend unproven treat-
ments or regimens for PMS that ap-
pear to be benign (ie, have no or min-
imal side effects) we hope to fulfill 
both these mandates. We need to fol-
low our patients to determine how ef-
fective the treatment is and to ensure 
that no serious side effects occur. 
Therapy would be discontinued if ei-
ther the patient saw no improvement 
or if suspected side effects developed. 
What happens when the so-called 
natural remedies like herbs, food sup-
plements, vitamins, or minerals are 
advocated by various business estab-
lishments? Large chain drug stores, 
health food establishments, or super-
markets can make huge profits from 
selling these "natural" remedies for 
PMS. No provision is made for eval-
uation or followup for adverse effects. 
I am always surprised by women who 
have a healthy skepticism for both 
physicians and prescribed medica-
tions, but who uncritically embrace 
natural remedies advocated by com-
mercial interests with clear profit mo-
tives. Perhaps it is the word "natural" 
that is appealing and denotes safety to 
many consumers. 
L-tryptophan is an amino acid nat-
urally occurring in many foods. No 
one knows how widely used it is or 
what constitutes the average dose. In 
an analysis of some 400 cases of the 
Eosinophilia-myalgia syndrome, dos-
ages ranged from 26 mg to 18,000 mg 
per day with a median dosage of 1,500 
mg per day. Many of those affected 
did not relate their symptoms to the 
L-tryptophan and kept consuming 
ever larger doses until they became 
incapacitated and were hospitalized. 
Before the epidemic was recognized, 
many patients did not report the use 
of the amino acid when describing 
symptoms because they didn't con-
sider it a medication. When patients 
were contacted after the association 
was made, all stated they had used L-
tryptophan and some were still using 
it. 
Whether it is the L-tryptophan it-
self or some contaminant in the man-
ufacturing process that causes the 
symptoms is unknown. The symptoms 
closely resemble toxic oil syndrome, 2 
which occurred in epidemic form in 
Spain in 1981. In that outbreak, the 
ingredient or contaminant in the cook-
ing oil that caused the symptoms was 
never established. A link between L-
tryptophan and the cooking oil is now 
being investigated. The Food and 
Drug Administration has issued ana-
tionwide recall of all L-tryptophan 
and L-tryptophan containing prod-
ucts. 
I wish I could come up with some 
moral to this tale. What I can do is to 
alert physicians to the association of 
L-tryptophan and this new syndrome 
and to suggest that we ask all our pa-
tients about natural remedies as well 
as medications they may be taking. 
For women with PMS, I advise cau-
tion in what you take whether pre-
scribed by a physician or your local 
grocer. 
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